Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

Background and Objective: Inhibition of thrombosis and platelet aggregation through a thromboxane synthetase inhibitor proved to be an effective and promising treatment for cardiovascular and/or cerebrovascular disease (CCVD) patients. This phase I study evaluated the safety, tolerability, and pharm...

Full description

Bibliographic Details
Main Authors: Chan Zou, Xiaocong Zuo, Jie Huang, Ye Hua, Shuang Yang, Xiaoyan Yang, Can Guo, Hongyi Tan, Jun Chen, Zhaoxing Chu, Qi Pei, Guoping Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Pharmacology
Subjects:
phase I trial
pyragrel
pharmacokinetics
pharmacodynamics
safety
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01231/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.01231/full

Similar Items